1326 related articles for article (PubMed ID: 31836957)
1. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
3. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
[TBL] [Abstract][Full Text] [Related]
5. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
[TBL] [Abstract][Full Text] [Related]
7. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
9. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
10. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity.
Diao K; Bian SX; Routman DM; Yu C; Ye JC; Wagle NA; Wong MK; Zada G; Chang EL
J Neurooncol; 2018 Sep; 139(2):421-429. PubMed ID: 29696531
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.
An Y; Jiang W; Kim BYS; Qian JM; Tang C; Fang P; Logan J; D'Souza NM; Haydu LE; Wang XA; Hess KR; Kluger H; Glitza IC; Mahajan A; Welsh JW; Lin SH; Yu JB; Davies MA; Hwu P; Sulman EP; Brown PD; Chiang VLS; Li J
Radiother Oncol; 2017 Oct; 125(1):80-88. PubMed ID: 28916225
[TBL] [Abstract][Full Text] [Related]
17. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
[TBL] [Abstract][Full Text] [Related]
18. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
20. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
